TCRR

TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit

TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting

TCR² Therapeutics to Present at the Needham Healthcare Conference

TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline

TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock